Form 4 for GRCE Grace Therapeutics, Inc.

Accepted 2023-09-27 00:00:00 ET · period of report 2023-09-25 · accession 0001062993-23-018542 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2023-09-27	2023-09-25	GRCE	Kavuru Vimal	Dir, 10%	P - Purchase	$1.85	+676.4K	1.19M	+132%	+$1.25M
DI	2023-09-27	2023-09-25	GRCE	Kavuru Vimal	Dir, 10%	P - Purchase	$0.13	+422.7K	422.7K	New	+$55.0K

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2023-09-25	P	A	676,371	$1.85	1,188,076	I See footnote	—	—	(F1) These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023. (F2) These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member.
2	Derivative	Common Warrants (right to buy)	2023-09-25	P	A	422,732	$0.13	422,732	I See footnote	$3.00 · 2023-09-25 to —	422,732 Common Shares	(F2) These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member. (F4) The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable. (F5) The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028.